Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

X
Trial Profile

A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rupitasertib (Primary) ; Elacestrant; Tamoxifen; Trastuzumab
  • Indications HER2 negative breast cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono
  • Most Recent Events

    • 22 Apr 2024 Data from this study were published in the Journal of Hematology & Oncology.
    • 19 Apr 2023 Results (n=20) assessing the exploratory correlative analyses in ER+ HER2-negative metastatic breast cancer patients in addition to nonclinical experiments to evaluate its role in the CDK4/6 and endocrine therapy (ET) resistant setting, presented at the 114th Annual Meeting of the American Association for Cancer Research.
    • 06 Apr 2023 According to Diaccurate Media Release, DIACC3010, expectedto enter phase 2/3 clinical trial in refractory ER positive and HER negative Metastatic breast cancer and phase 1 trial in glioblastoma multiforme.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top